Longeveron Inc. - notizie pubblicate 249 - letture 2.503


Longeveron Inc.

LONGEVERON INC.

Initial Registration Statement for Employee Benefit Plan Form S 8

As filed with the securities and exchange commission on july 10, 2024 registration no. 333- united states securities and exchange commission washington, d.c. 20549 form s-8 registr ...

10.07.2024
Longeveron Inc.

LONGEVERON INC.

Supplemental Prospectus - Form 424B3

Filed pursuant to rule 424(b)(3) registration no. 333-280577 prospectus 3,563,764 shares of class a common stock this prospectus relates to the re-sale or other disposition from ti ...

10.07.2024
Longeveron Inc.

LONGEVERON INC.

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease

Longeveron® announces u.s. fda grants lomecel-b™ regenerative medicine advanced therapy (rmat) designation for the treatment of mild alzheimer's disease - lomecel-b™ appears t ...

10.07.2024
Longeveron Inc.

LONGEVERON INC.

Notice of Effectiveness - Form EFFECT

Notice of effectiveness united states securities and exchange commission washington, d.c. 20549 notice of effectiveness effectiveness date: july 9, 2024 5:00 p.m. form: s-1 cik: 00 ...

10.07.2024
Longeveron Inc.

LONGEVERON INC.

Neha Motwani Elected to Longeveron® Board of Directors

Miami, july 09, 2024 (globe newswire) -- longeveron inc. (nasdaq: lgvn), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threate ...

09.07.2024
Longeveron Inc.

LONGEVERON INC.

Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

Gene therapy pioneer roger hajjar, md, elected to longeveron® board of directors miami, july 08, 2024 (globe newswire) -- longeveron inc. (nasdaq: lgvn), a clinical stage regenera ...

08.07.2024
Longeveron Inc.

LONGEVERON INC.

Statement of Changes in Beneficial Ownership - Form 4

Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...

03.07.2024
Longeveron Inc.

LONGEVERON INC.

Submission of Matters to a Vote of Security Holders Form 8 K

Item 5.07 submission of matters to a vote of security holders. (a) the company's annual meeting of stockholders was held on july 2, 2024. (b) three (3) proposals were submitted by ...

03.07.2024
Longeveron Inc.

LONGEVERON INC.

Initial Registration Statement Form S 1

As filed with the securities and exchange commission on june 28, 2024 registration no. 333- united states securities and exchange commission washington, d.c. 20549 form s-1 registr ...

28.06.2024
Longeveron Inc.

LONGEVERON INC.

Initial Registration Statement Form S 1

As filed with the securities and exchange commission on june 28, 2024 registration no. 333- united states securities and exchange commission washington, d.c. 20549 form s-1 registr ...

28.06.2024
Longeveron Inc.

LONGEVERON INC.

Notice of Sales of Unregistered Securities - Form D

Sec form d the securities and exchange commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. the reader shou ...

25.06.2024
Longeveron Inc.

LONGEVERON INC.

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds Form 8 K

Longeveron announces exercise of warrants for $4.4 million gross proceeds miami, june 17, 2024 (globe newswire) -- longeveron inc. (nasdaq: lgvn) ("longeveron" or the &qu ...

19.06.2024
Longeveron Inc.

LONGEVERON INC.

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

Longeveron raises $4.4 million in gross proceeds from warrant exercise transaction miami, june 18, 2024 (globe newswire) -- longeveron inc. (nasdaq: lgvn) ("longeveron" o ...

18.06.2024
Longeveron Inc.

LONGEVERON INC.

Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024

Longeveron® to present at the virtual life sciences investor forum on june 20, 2024 miami, june 17, 2024 (globe newswire) -- longeveron inc. (nasdaq: lgvn), a clinical stage regen ...

17.06.2024
Longeveron Inc.

LONGEVERON INC.

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds

Miami, june 17, 2024 (globe newswire) -- longeveron inc. (nasdaq: lgvn) ("longeveron" or the "company"), a clinical stage regenerative medicine biotechnology co ...

17.06.2024
Condividi